Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Business Ethics
Contact us
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2011
Press release archive
Webcast and presentation
MEDIA center
Press Release 2011
Press Release Archive
Webcast and Presentation
Dec 12, 2011
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401
Dec 12, 2011
Transition Therapeutics Appoints New Chief Financial Officer
Dec 09, 2011
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Dec 01, 2011
Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results
Nov 22, 2011
Transition Therapeutics Completes US$5 Million Private Placement
Nov 21, 2011
Transition Therapeutics Announces US$5 Million Private Placement
Sep 27, 2011
Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
Sep 19, 2011
Transition Therapeutics Announces Fiscal 2011 Year End Financial Results
Sep 16, 2011
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
Jul 15, 2011
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
Jun 07, 2011
Transition Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference
May 10, 2011
Transition Therapeutics Announces Third Quarter Fiscal 2011 Financial Results
Feb 22, 2011
Transition Therapeutics Inc.: News Release
Feb 07, 2011
Transition Therapeutics Announces Second Quarter Fiscal 2011 Financial Results
Feb 04, 2011
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2011 Financial Results on Monday, February 7th, at 4:30 P.M. EST
© 2011 Transition Therapeutics Inc.
